Please login to the form below

Not currently logged in

Pfizer appoints diabetes expert Morris Birnbaum

He takes up post as chief scientific officer for cardiovascular and metabolic diseases

Morris Birnbaum PfizerPfizer has appointed prominent academic Dr Morris Birnbaum as chief scientific officer for its research into cardiovascular and metabolic diseases.

Dr Birnbaum most recently served as Willard Ware professor of diabetes and metabolic diseases and associate dean for biomedical core resources at the Perelman School of Medicine at the University of Pennsylvania.

In his academic career he has authored more than 200 scientific papers and has built an expertise in intracellular metabolism - a key component to understanding diabetes and its relationship to cardiovascular disease.

“His scientific credentials and knowledge will help Pfizer pursue our goals to achieve industry leadership from the strong position that we currently hold, and to deliver unique therapies for patients,” said Dr Rod MacKenzie, group senior VP and head of PharmaTherapeutics R&D.

Pfizer's interests in the area include a collaboration with Merck & Co on the sodium glucose co-transporter (SGLT2) inhibitor ertugliflozin to treat diabetes. The company is also developing bococizumab for hypercholesterolemia.

5th June 2014

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

Haseeb Ahmad
Can value-based healthcare take off and reach for the skies?
Are companies willing to contribute to the change in the healthcare system?...
Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...